Top

American Journal of Cardiovascular Drugs

Published in:

01-10-2011 | Leading Article

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

Authors: Prof. Daniel P. Judge, David A. Kass, W. Reid Thompson, Kathryn R. Wagner

Published in: American Journal of Cardiovascular Drugs | Issue 5/2011

Abstract

Cardiac dysfunction is a frequent manifestation of Duchenne muscular dystrophy (DMD) and a common cause of death for individuals with this condition. Early diastolic dysfunction and focal fibrosis proceed to dilated cardiomyopathy (DCM), complicated by heart failure and arrhythmia in most patients. Improvements in the management of respiratory insufficiency in DMD have improved lifespan and overall prognosis, but heart failure and sudden death continue to impact survival and quality of life for people with DMD. Since the specific mechanisms resulting in heart failure for people with DMD are poorly understood, current treatments are not targeted, but rely on approaches that are considered standard for DCM. These approaches include angiotensin-converting enzyme (ACE) inhibitors and β-adrenoceptor antagonists. Data from one trial in DMD support the use of ACE inhibitors before the onset of left ventricular dysfunction. Angiotensin receptor blockers have shown similar efficacy to ACE inhibitors in numerous studies of dilated cardiomyopathy, and are a good choice for patients who cannot tolerate ACE inhibition. The pathogenesis of DMD-associated cardiomyopathy may be similar to other genetic disorders of the cytoskeletal complex of ventricular myocytes, though unique features offer targeted opportunities to impact treatment. Novel areas of investigation are focused on the regulatory role of dystrophin in relation to neuronal nitric oxide synthase (nNOS) and transient receptor potential canonical channels (TRPC). Inhibition of phosphodiesterase-5 (PDE5) addresses several aspects of regulatory dysfunction induced by dystrophin deficiency, and studies with PDE5-inhibitors have shown benefits in murine models of DMD. PDE5-inhibitors are currently under investigation in at least one study in humans. This article focuses on mechanisms of cardiac dysfunction, as well as potential targets for pharmacologic manipulation to prevent or improve cardiomyopathy in DMD.

Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50 (3): 509–17.PubMedCrossRef

Tuffery-Giraud S, Beroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 2009; 30 (6): 934–45.PubMedCrossRef

Becker PE. Two families of benign sex-linked recessive muscular dystrophy. Rev Can Biol 1962; 21: 551–66.PubMed

Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. Neuromuscul Disord 2003; 13 (2): 166–72.PubMedCrossRef

Boland BJ, Silbert PL, Groover RV, et al. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol 1996; 14 (1): 7–12.PubMedCrossRef

Wagner KR, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 2007; 1772 (2): 229–37.PubMedCrossRef

Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy. Part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2009; 9 (1): 77–93.PubMedCrossRef

Markham LW, Michelfelder EC, Border WL, et al. Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J Am Soc Echocardiogr 2006; 19 (7): 865–71.PubMedCrossRef

Hoffman EP, Brown Jr RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–28.PubMedCrossRef

10.

Monaco AP, Neve RL, Colletti-Feener C, et al. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986; 323 (6089): 646–50.PubMedCrossRef

11.

Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991; 66 (6): 1121–31.PubMedCrossRef

12.

Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004; 94 (8), 1023–31.PubMedCrossRef

13.

Heydemann A, Ceco E, Lim JE, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest 2009; 119 (12): 3703–12.PubMedCrossRef

14.

Goldstein JA, Kelly SM, Lopresti PP, et al. SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy. Hum Mol Genet 2010; 20 (5), 894–904.PubMedCrossRef

15.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23): 1429–35.CrossRef

16.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293–302.CrossRef

17.

Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327 (10): 669–77.PubMedCrossRef

18.

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 (10): 685–91.CrossRef

19.

Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45 (6): 855–7.PubMedCrossRef

20.

Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 2007; 154 (3): 596–602.PubMedCrossRef

21.

Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747–52.PubMedCrossRef

22.

Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582–7.PubMedCrossRef

23.

Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13 (2): 204–10.PubMedCrossRef

24.

Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007; 116 (1): 49–56.PubMedCrossRef

25.

Matsumura T, Tamura T, Kuru S, et al. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med 2010; 49 (14), 1357–63.PubMedCrossRef

26.

Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med 1989; 320 (24): 1592–7.PubMedCrossRef

27.

Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromusc Disord 2008; 18 (5): 365–70.PubMedCrossRef

28.

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10): 709–17.PubMedCrossRef

29.

Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11–21.PubMedCrossRef

30.

Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351 (6): 543–51.PubMedCrossRef

31.

Viollet L, Gailey S, Thornton DJ, et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 2009; 40 (3): 438–42.PubMedCrossRef

32.

Brenman JE, Chao DS, Gee SH, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 1996; 84 (5): 757–67.PubMedCrossRef

33.

Kobzik L, Reid MB, Bredt DS, et al. Nitric oxide in skeletal muscle. Nature 1994; 372 (6506): 546–8.PubMedCrossRef

34.

Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347 (6295): 768–70.PubMedCrossRef

35.

Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995; 82 (5): 743–52.PubMedCrossRef

36.

Wehling-Henricks M, Jordan MC, Roos KP, et al. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005; 14 (14): 1921–33.PubMedCrossRef

37.

Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009; 119 (3): 624–35.PubMedCrossRef

38.

Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008; 456 (7221): 511–5.PubMedCrossRef

39.

Suzuki N, Motohashi N, Uezumi A, et al. NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 2007; 117 (9): 2468–76.PubMedCrossRef

40.

Crosbie RH, Straub V, Yun HY, et al. Mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 1998; 7 (5): 823–9.PubMedCrossRef

41.

Chao DS, Silvagno F, Bredt DS. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase. J Neurochem 1998; 71 (2): 784–9.PubMedCrossRef

42.

Rando TA. Role of nitric oxide in the pathogenesis of muscular dystrophies: a “two hit” hypothesis of the cause of muscle necrosis. Microsc Res Tech 2001; 55 (4): 223–35.PubMedCrossRef

43.

Hopf FW, Turner PR, Steinhardt RA. Calcium misregulation and the pathogenesis of muscular dystrophy. Subcell Biochem 2007; 45: 429–64.PubMedCrossRef

44.

Jung C, Martins AS, Niggli E, et al. Dystrophic cardiomyopathy: amplification of cellular damage by Ca2+ signalling and reactive oxygen species-generating pathways. Cardiovasc Res 2008; 77 (4): 766–73.PubMedCrossRef

45.

Reggiani C. Between channels and tears: aim at ROS to save the membrane of dystrophic fibres. J Physiol 2008; 586 (7): 1779.PubMedCrossRef

46.

Whitehead NP, Streamer M, Lusambili LI, et al. Streptomycin reduces stretchinduced membrane permeability in muscles from mdx mice. Neuromuscul Disord 2006; 16 (12): 845–54.PubMedCrossRef

47.

Whitehead NP, Pham C, Gervasio OL, et al. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol 2008; 586 (7): 2003–14.PubMedCrossRef

48.

Williams IA, Allen DG. Intracellular calcium handling in ventricular myocytes from mdx mice. Am J Physiol Heart Circ Physiol 2007; 292 (2): H846–55.PubMedCrossRef

49.

Gervasio OL, Whitehead NP, Yeung EW, et al. TRPC1 binds to caveolin-3 and is regulated by Src kinase-role in Duchenne muscular dystrophy. J Cell Sci 2008; 121 (Pt 13): 2246–55.PubMedCrossRef

50.

Vandebrouck A, Sabourin J, Rivet J, et al. Regulation of capacitative calcium entries by alpha1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of alpha1-syntrophin. Faseb J 2007; 21 (2): 608–17.PubMedCrossRef

51.

Woo JS, Kimdo H, Allen PD, et al. TRPC3-interacting triadic proteins in skeletal muscle. Biochem J 2008; 411 (2): 399–405.PubMedCrossRef

52.

Millay DP, Goonasekera SA, Sargent MA, et al. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci U S A 2009; 106 (45): 19023–8.PubMedCrossRef

53.

Hofmann T, Obukhov AG, Schaefer M, et al. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 1999; 397 (6716): 259–63.PubMedCrossRef

54.

Spassova MA, Hewavitharana T, Xu W, et al. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc Natl Acad Sci U S A 2006; 103 (44): 16586–91.PubMedCrossRef

55.

Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100 (3): 309–27.PubMedCrossRef

56.

Francis SH, Corbin JD. Purification of cGMP-binding protein phosphodiesterase from rat lung. Methods Enzymol 1988; 159: 722–9.PubMedCrossRef

57.

Stacey P, Rulten S, Dapling A, et al. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998; 247 (2): 249–54.PubMedCrossRef

58.

Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338 (20): 1397–404.PubMedCrossRef

59.

Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20): 2148–57.PubMedCrossRef

60.

Salloum F, Yin C, Xi L, et al. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003; 92 (6): 595–7.PubMedCrossRef

61.

Borlaug BA, Melenovsky V, Marhin T, et al. Sildenafil inhibits betaadrenergic-stimulated cardiac contractility in humans. Circulation 2005; 112 (17): 2642–9.PubMedCrossRef

62.

Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11 (2): 214–22.PubMedCrossRef

63.

Forfia PR, Lee M, Tunin RS, et al. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007; 49 (10): 1079–88.PubMedCrossRef

64.

Koitabashi N, Aiba T, Hesketh GG, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation: novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 2010; 48 (4): 713–24.PubMedCrossRef

65.

Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010; 107 (44): 19079–83.PubMedCrossRef

66.

Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4 (1): 8–17.PubMedCrossRef

67.

Yasuda S, Townsend D, Michele DE, et al. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005; 436 (7053): 1025–9.PubMedCrossRef

68.

Sharp NJ, Kornegay JN, Van Camp SD, et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992; 13 (1): 115–21.PubMedCrossRef

69.

Townsend D, Turner I, Yasuda S, et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010; 120 (4): 1140–50.PubMedCrossRef

Title: Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy
Authors: Prof. Daniel P. Judge
David A. Kass
W. Reid Thompson
Kathryn R. Wagner
Publication date: 01-10-2011
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 5/2011
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.2165/11594070-000000000-00000

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy Subjects

Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination

The Role of Direct Renin Inhibition in Clinical Practice

Lomitapide

Blood Pressure-Lowering Response to Amlodipine as a Determinant of the Antioxidative Activity of Small, Dense HDL3

Extracorporeal Shock Wave Therapy for Ischemic Cardiovascular Disorders

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page